cellular & molecular immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/gradimm09tumor.pdf ·...
TRANSCRIPT
![Page 1: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/1.jpg)
Cellular & Molecular Cellular & Molecular ImmunologyImmunology
Cancer and the Immune SystemCancer and the Immune System
Nicholas M. Ponzio, Ph.D.Nicholas M. Ponzio, Ph.D.Department of Pathology & Laboratory MedicineDepartment of Pathology & Laboratory Medicine
May 4, 2009May 4, 2009
![Page 2: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/2.jpg)
Lecture Overview• Tumor “antigens” as targets of immune attack
• Potential host immune mechanisms that protect against development and growth of cancer cells
• Ways in which tumor cells circumvent or neutralize host immune mechanisms
• Immunotherapeutic strategies for treatment of cancer patients
![Page 3: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/3.jpg)
a group of diseases characterized by uncontrolled growth and spread of abnormal cells
What is Cancer?What is Cancer?
![Page 4: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/4.jpg)
Cancer FactoidsCancer Factoids
• Since 2000, nearly 10 million new cancer cases have been diagnosed
• More than 1.2 million Americans develop cancer each year
• A new cancer is diagnosed every 30 seconds in the United States
• Cancer is the second leading cause of death after heart disease in the United States
![Page 5: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/5.jpg)
![Page 6: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/6.jpg)
What causes cancer?What causes cancer?
DonDon’’t know the exact causes, but evidence t know the exact causes, but evidence suggests contributing factors include:suggests contributing factors include:
Genetic influences Genetic influences –– oncogenesoncogenes
Environmental influences Environmental influences –– (carcinogens) (carcinogens) found in tobacco products, industrial found in tobacco products, industrial pollutants, pesticides, fertilizers, etc.pollutants, pesticides, fertilizers, etc.
Infectious organisms Infectious organisms –– some viruses and some viruses and bacteria may be bacteria may be oncogeniconcogenic
Suppression of immune protective mechanismsSuppression of immune protective mechanisms
![Page 7: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/7.jpg)
How do cancer cells differ from normal How do cancer cells differ from normal cells?cells?
Autonomous growth Autonomous growth –– failure to respond to failure to respond to regulatory growth controlsregulatory growth controls
Ability to break away from the original tumor mass Ability to break away from the original tumor mass and migrate/grow in other tissues and migrate/grow in other tissues –– Metastasis Metastasis
Expression of Expression of ““newnew”” molecules (cell surface or molecules (cell surface or intracellular) that are not present on normal cellsintracellular) that are not present on normal cells
These new molecules (antigens) are potential These new molecules (antigens) are potential targets for the immune responsetargets for the immune response
![Page 8: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/8.jpg)
TumorTumor rejection is an immune responserejection is an immune response
Remove tumor
![Page 9: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/9.jpg)
Fig 17Fig 17--22
Tumor Antigens
![Page 10: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/10.jpg)
Table 17-1: Tumor Antigens
PSA; CD10 (ALL); Ig idiotypes (B lymphomas)
Differentiation Ag
Papilloma viruses (cervical Ca); EBNA-1 (EBV-assoc lymphomas); SV40 T antigen (rodent tumors)
MART (melanomas; normally expressed in melanocytes)
CEA (GI and other Ca; normal in liver & during inflammation); AFP (Alpha-fetoprotein)
Oncofetal antigens
Oncogenic viruses
Overexpressed normal genes
Ras mutations (~10% human Ca); Her2/neu (breast & other Ca)
Oncogenes & tumor suppressor genes
Examples of Human Tumor AgsAntigens From
![Page 11: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/11.jpg)
Oncofetal Antigens
Carcinoembryonic Antigen; Alpha fetoprotein
![Page 12: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/12.jpg)
![Page 13: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/13.jpg)
Normal vs. malignant B cells
• Malignant transformation can occur at any stage of development
• Daughter cells within the malignant clone express many of the same surface molecules as their normal counterparts
• Malignant cells exhibit unregulated growth
![Page 14: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/14.jpg)
CD10 on normal and malignant B cells
<10% of PBMC are CD10+
100% of cells within the malignant clone
are CD10+
![Page 15: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/15.jpg)
MHC IMHC II
![Page 16: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/16.jpg)
Flow cytometry and Fluorescence-Activated Cell Sorting (FACS)
![Page 17: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/17.jpg)
Immunophenotype of a patient with ???Chronic Lymphocytic (B cell) LymphomaCLL
Positive for:
CD5, CD20, CD19, CD23 (FcR);
kappa light chain
Negative for:
CD3; lambda light chain
![Page 18: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/18.jpg)
![Page 19: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/19.jpg)
![Page 20: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/20.jpg)
![Page 21: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/21.jpg)
Ig expression during B lymphocyte maturation
![Page 22: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/22.jpg)
Electrophoresis patterns
Normal
Multiple Myeloma
![Page 23: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/23.jpg)
Concept of Immunosurveillance(Lewis Thomas & McFarland Burnet; 1959)
Immune system functions to recognize and destroy clones of malignant cells before they develop into clinically relevant tumors. (T cells)
Based on this concept, one would expect a higher incidence of cancer in people who manifest T cell immunodeficiencies.
However, there is not an inordinately higher frequency of common cancers (breast, prostate, colon, lung) associated with T cell immunodeficiency states
![Page 24: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/24.jpg)
![Page 25: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/25.jpg)
Immunodeficiency (ID) and Cancer
KSHV-8Kaposi’s Sarcoma
Hepatitis BLiver
PapillomaCervical EBVB cell lymphoma
EBVB cell (Burkitt’s)lymphoma
Infectious Disease; Malaria
PapillomaSkin
Immuno-suppression for transplants or due to AIDS
EBVB cell lymphomaInherited Virus involvedType of CancerCause of ID
![Page 26: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/26.jpg)
CR2 (CD21) = EBV Receptor
![Page 27: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/27.jpg)
![Page 28: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/28.jpg)
Potential Host Immune Mechanisms Against the Development of Cancer
• Anti-tumor antibodies
• Tumor-specific Cytotoxic T Lymphocytes (CTL)
• Natural Killer (NK) cells (resting or activated)
• Activated Macrophages
![Page 29: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/29.jpg)
Potential Host Immune Mechanisms: Antibody response against tumor antigens
![Page 30: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/30.jpg)
Potential Host Immune Mechanisms: Stimulation of tumor specific Cytotoxic T Lymphocytes (CTL)
Fig 17Fig 17--33
![Page 31: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/31.jpg)
Potential Host Immune Mechanisms: Resting and cytokine activated NK cells
![Page 32: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/32.jpg)
![Page 33: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/33.jpg)
MHC I
MHC II
Potential Host Immune Mechanisms: Resting and cytokine activated macrophages
![Page 34: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/34.jpg)
ADCC Effector Cells = NK cells, macrophages, eosinophils
Antibody Dependent Cell-mediated Cytotoxicity (ADCC)
![Page 35: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/35.jpg)
Paradox: Tumor growth can occur in spite of immune reactivity
![Page 36: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/36.jpg)
Genetic FactorsInnate & Adaptive
Immunity
Tumor
Escape
Mechanisms
![Page 37: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/37.jpg)
Tumor escape mechanisms:Location Location Location
![Page 38: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/38.jpg)
Tumor escape mechanisms:
Not all tumor antigens are created equal
(i.e., equally immunogenic)
![Page 39: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/39.jpg)
Tumor Cell
MHC molecules present peptide antigens
![Page 40: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/40.jpg)
Fig 17Fig 17--4: Tumor Escape 4: Tumor Escape MechanismsMechanisms
![Page 41: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/41.jpg)
Tumor escape mechanisms:Failure to express co-stimulatory molecules
The most common cancers (breast, prostate, lung, colon) do not express co-stimulatory
molecules
![Page 42: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/42.jpg)
The major goals of immunotherapy:The major goals of immunotherapy:
•• to identify tumor antigensto identify tumor antigens
•• to stimulate the patientto stimulate the patient’’s own immune system s own immune system to recognize antigens on tumor cells and mount to recognize antigens on tumor cells and mount effective mechanisms to destroy the tumor cells effective mechanisms to destroy the tumor cells
•• to be used with other forms of treatment to seekto be used with other forms of treatment to seekout and destroy tumor cells at metastatic sitesout and destroy tumor cells at metastatic sites
•• to be effective with minimal side effectsto be effective with minimal side effects
![Page 43: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/43.jpg)
Immunotherapy Against Cancer
Antibodies coupled to drugs, toxins, radioisotopes; CTL
Specific
CytokinesNon-specificPassive
Tumor vaccinesSpecificBCG; C. parvumNon-specific
Active
Active immunotherapy requires the recipient to respond to the agent being administered
![Page 44: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/44.jpg)
Table 17-2: Tumor Vaccines
Various carcinomasDC + tumor Ag gene
Melanoma; Renal CaHeat Shock Protein
MelanomaLysates
MelanomaAdeno or Vacciniawith tumor Ag
Viral Vectors
MelanomaImm w tumor Ag encoding plasmids
DNA Vaccines
Melanoma; NHL; ProstateDC + tumor AgAPC-based Vaccines
MelanomaMelanoma AntigenPurified tumor antigen
Melanoma; Colon CaCells Killed tumor vaccine
Clinical TrialsPreparationType
![Page 45: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/45.jpg)
Fig 17Fig 17--5: Tumor Vaccines5: Tumor Vaccines
![Page 46: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/46.jpg)
Table 17-4: Systemic Cytokine Therapy for Tumors
Abnormal liver functionPhase I Toxicity; Melanoma and others
Septic Shock Syndrome
Melanoma; Sarcoma
Bone painRoutine use to promote BM recovery in patients
GM-CSF
Fever; abnormal liver; CNS toxicicty; hypotension
Renal (no benefit seen)
IL-6
IL-12
TNF
Vascular leak; shock; pulmonary edema
Melanoma; Renal; Colon (<15% response)
IL-2ToxicityClinical TrialsCytokine
![Page 47: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/47.jpg)
Fig 17Fig 17--6: Cytokine Gene6: Cytokine Gene--transfected Tumor Cellstransfected Tumor Cells
![Page 48: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/48.jpg)
Table 17-5: mAbs for Cancer Therapy
Ovarian cancerMouse mAbCA-125
B cell lymphomaHumanized mouse mAb
B cell lymphomaHumanized mouse mAb
MelanomaHumanized mouse mAb
GD3 Ganglioside
GI and lung cancers
Humanized mouse mAb
CEA
CD10
CD20
Breast Ca (approved for clinical use)
Humanized mouse mAb
Her-2/NeuClinical TrialsForm of mAb usedSpecificity
![Page 49: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/49.jpg)
B-Cell Lymphomas Express Several Antigens That Can Be Targeted
Adapted from Press. Semin Oncol. 1999;26:5(suppl 14):58.
HLA-DR (MHC II)
sIg
CD19
CD22
CD23
CD40CD80
CD20
![Page 50: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/50.jpg)
CD20 Is Not Expressed on Stem Cells or Plasma Cells
Pluripotent stem cell
Lymphoid stem cell
Pre-B cell B cell Activated B cell
Plasma cell
Bone Marrow Blood, Lymph
Press. Semin Oncol. 1999;26:5(suppl 14):58.
CD20
![Page 51: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/51.jpg)
BEXXAR: Characteristics
131131II
Tyrosine Tyrosine labellabel
TositumomabTositumomab(Murine IgG2a) (Murine IgG2a)
CD20 BindingCD20 Binding
γγ and and ββ--radiationradiation
![Page 52: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/52.jpg)
Tumors can develop resistance to treatment
Adapted from Press. Semin Oncol. 1999;26:5(suppl 14):58.
HLA-DR (MHC II)
sIg
CD19
CD22
CD23
CD40CD80
CD20
Resistance to continued treatment
Downregulation or mutation of
surface molecules
Anti-CD20 mAb
![Page 53: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/53.jpg)
![Page 54: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/54.jpg)
![Page 55: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/55.jpg)
Generation of tumor-specific CTL clones
![Page 56: Cellular & Molecular Immunologynjms.rutgers.edu/gsbs/olc/mci/prot/2009/GradImm09Tumor.pdf · Cellular & Molecular Immunology ... Ability to break away from the original tumor mass](https://reader031.vdocuments.mx/reader031/viewer/2022020413/5b4581087f8b9a75778bab06/html5/thumbnails/56.jpg)